Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.36
+9.8%
$0.34
$0.25
$0.48
$30.83M1.48913,992 shs214,616 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.47
-2.0%
$1.51
$0.94
$2.34
$23.63M0.96245,750 shs102,746 shs
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
+3.46%+5.28%-2.45%+22.53%-11.45%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-2.60%-5.66%-6.25%+14.50%-13.79%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
1.7699 of 5 stars
3.50.00.00.01.91.70.0
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.2743 of 5 stars
0.05.00.00.00.60.00.0
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.00
Buy$3.88982.40% Upside
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00
N/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$1.27M25.58N/AN/A$0.08 per share4.48
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
-$13M-$0.08N/AN/AN/A-714.16%-122.44%-88.40%N/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.70N/AN/AN/A-87.90%-78.69%N/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
0.02
1.15
0.98
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92

Institutional Ownership

CompanyInstitutional Ownership
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.87%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
10.38%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A

Insider Ownership

CompanyInsider Ownership
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
31.48%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
16.43%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
4.60%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
6190.81 million54.60 millionN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2016.07 million14.92 millionOptionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGC Pharma stock logo

IGC Pharma NYSEMKT:IGC

$0.36 +0.03 (+9.78%)
Closing price 03:59 PM Eastern
Extended Trading
$0.36 0.00 (-0.28%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.47 -0.03 (-2.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.47 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Pharmaxis stock logo

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)
As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.